Literature DB >> 495514

Pharmacokinetics of digoxin in patients with acute myocardial infarction.

U R Korhonen, A J Jounela, A J Pakarinen, P J Pentikäinen, J T Takkunen.   

Abstract

The effects of acute myocardial infarction on the pharmacokinetics of digoxin were studied. Digoxin, 0.75 mg, was given orally to 12 patients with left-sided cardiac failure due to acute myocardial infarction and to 9 healthy control subjects. Serum concentration of digoxin in the first 4 hours and the area under the serum concentration-time curve in the first 12 hours after administration of the drug were lower in patients with infarction than in control subjects (P less than 0.01). The 24 hour area under the concentration curve, the amount excreted in urine and the renal clearance did not differ between the groups. The 24 hour area under the concentration curve correlated with the predigoxin pulmonary capillary wedge pressure and with heart rate (P less than 0.01). The decrease of renal clearance of digoxin was related to the serum activity of MB isoenzyme of creatine kinase (P less than 0.001). Morphine reduced and delayed the peak serum concentrations of digoxin (P less than 0.001). Thus, the absorption of oral digoxin was slower and the peak concentrations remained lower in patients with acute myocardial infarction than in healthy control subjects. However, the total amount of digoxin absorbed was unchanged.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 495514     DOI: 10.1016/0002-9149(79)90187-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.

Authors:  C R Kumana; V S Rambihar; K Willis; R N Gupta; P H Tanser; J A Cairns; R A Wildeman; M Johnston; A L Johnson; M Gent
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

Review 5.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 6.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

7.  Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.

Authors:  R Wise; N Wright; P J Wills
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.